

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date:

April 21, 1999

(Signature of person mailing paper)

PATENT #5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of)	Group Art Unit: 1614
)	
Arimilli et al.)	Attorney Docket No. 221.P1C
)	
Serial No: 09/187,763)	Examiner: M. Ambrose
)	
Filed: November 6, 1998)	
)	
Title: Antiviral Phosphonmethoxy Nucleotide)	
<u>Analogues Having Increased Oral Bioavailability</u>)	

TERMINAL DISCLAIMER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Gilead Sciences, Inc., a Delaware corporation, having an address at 333 Lakeside Drive, Foster City, California 94404, certifies to the best of Gilead's knowledge and belief that Gilead Sciences, Inc. is the owner of the entire right, title and interest to U.S. application serial No. 09/187,763 (hereafter '763), and U.S. application serial No. 08/900,746 (hereafter '746); evidence of ownership of '763 and '746 is the assignment recorded on January 26, 1998 at Reel 8929, Frame 0225.

Gilead Sciences, Inc. hereby disclaims the terminal part of any patent granted on

'763 which would extend beyond the expiration date of any patent to issue on '746 and

any patent granted on the '763 application will be enforceable only during


04/26/1999 PWILSON 00000001 071250 09187763
Sale Ref: 08089003 Date: 071250 09187763
01 FC:148 110.00 CH

the period that the legal title to any patent issuing on the '746 patent application is the same as the legal title to any patent granted on '763. This agreement runs with any patent granted on '763 and is binding on Gilead Sciences, Inc., its successors or assigns.

Gilead Sciences, Inc. does not disclaim any terminal part of any patent that issues on '763 prior to its expiration date as presently shortened by this terminal disclaimer of the '746 application in the event that any patent granted on the '746 application (1) expires for failure to pay a maintenance fee, (2) is held unenforceable or found invalid by a court of competent jurisdiction and all appeals from that court's final judgment are exhausted, (3) is disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), (4) has all claims canceled by a reexamination certificate, or (5) is otherwise terminated prior to its statutory term.

Please charge Deposit Account No. 07-1250 the sum of \$110.00 and for any fee deficiency which may be due. A duplicate of this disclaimer is attached.

Dated: April 21, 1999



By: Max Hensley

Title: Vice President for Intellectual Property

Phone: (650) 522-5878

Fax: (650) 522-5899

E-mail: Max_Hensley@Gilead.com

GAL 1613

The information in this facsimile is confidential and is intended for the sole use of the addressee designated below. If this facsimile has been misdirected, kindly return it by postal service to Gilead Sciences, Inc. If you do not receive all pages clearly, please telephone (650) 522-5535.

RECEIVED



GILEAD SCIENCES, INC.
333 Lakeside Drive
Foster City, California 94404
Telephone: 650/522-5535 or 650/574-3000
Telefacsimile: 650/522-5899

APR 28 1999
MATRIX-CUSTOMER
SERVICE CENTER

Date: April 21, 1999

Telefax: (703) 308-4556

To: Assistant Commissioner
for Patents
Washington, D.C. 20231

Re: In re application of: Arimilli et al
Serial No.: 09/187,763
Filed: November 6, 1998

Attorney Docket No. 221.P1C
Group No. 1613
Examiner: M. Ambrose

For: Antiviral Phosphonomethoxy Nucleotide Analogs
Having Increased Oral Bioavailability

From: Max D. Hensley, Reg. 27,043

Total Number of Pages Including Cover Sheet: 8

Certification of Facsimile Transmission

I hereby certify that this paper along with the following documents are being facsimile transmitted to the Patent and Trademark Office and that the original documents are being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Amendment Transmittal
Amendment
Terminal Disclaimer

Robin Torres

Type or print name of person signing certification

Robin Torres
Signature

April 21, 1999
Date